Emerging topical treatments for psoriasis
- PMID: 24274614
- DOI: 10.1517/14728214.2013.861418
Emerging topical treatments for psoriasis
Abstract
Introduction: Psoriasis is an immune-mediated chronic inflammatory skin disease which classically presents as erythematous, scaly plaques affecting extensor surfaces of the limbs, scalp and trunk. Approximately 80% of patients have a mild-to-moderate form routinely treated with topical medications, whereas phototherapy, systemic and biological therapies are typically reserved for treatment of moderate-to-severe psoriasis.
Areas covered: The major advances in psoriasis therapy in the past 15 years have been in new immunomodulatory and biological molecules, with a significant unmet need to have new, efficient and safe topical treatment options for the large percentage of patients for whom systemic therapy is not indicated. The available topical therapies (corticosteroids and vitamin D3 analogs) have remained relatively unchanged over the past several decades. This article reviews emerging topical drugs and formulations currently under evaluation in clinical trials.
Expert opinion: The time is right for a revolution in our topical therapy armamentarium. It has lagged significantly behind the systemic biological evolution of new drug development. Our large psoriasis population with mild-to-moderate psoriasis certainly deserves potent but safe and innovative topical agents with a new mode of action as well as with long-lasting clinical efficacy.
Similar articles
-
Emerging oral drugs for psoriasis.Expert Opin Emerg Drugs. 2015 Jun;20(2):209-20. doi: 10.1517/14728214.2015.1010509. Epub 2015 Feb 3. Expert Opin Emerg Drugs. 2015. PMID: 25643592 Review.
-
Topical vitamin D analogs available to treat psoriasis.Skinmed. 2012 Nov-Dec;10(6):356-60. Skinmed. 2012. PMID: 23346664 Review.
-
Topical management of psoriasis - corticosteroids and sparing corticosteroid therapy.Acta Dermatovenerol Croat. 2006;14(3):188-96. Acta Dermatovenerol Croat. 2006. PMID: 17010269 Review.
-
Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.Eur J Dermatol. 2016 Jan-Feb;26(1):3-8. doi: 10.1684/ejd.2015.2663. Eur J Dermatol. 2016. PMID: 26552963 Review.
-
Topical psoriasis therapy.Am Fam Physician. 1999 Feb 15;59(4):957-62, 964. Am Fam Physician. 1999. PMID: 10068717 Review.
Cited by
-
Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.BMC Gastroenterol. 2014 Dec 19;14:214. doi: 10.1186/s12876-014-0214-x. BMC Gastroenterol. 2014. PMID: 25523080 Free PMC article.
-
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.Br J Clin Pharmacol. 2017 May;83(5):991-1001. doi: 10.1111/bcp.13185. Epub 2017 Jan 10. Br J Clin Pharmacol. 2017. PMID: 27859546 Free PMC article. Clinical Trial.
-
Cooling Blood and Detoxicating Formula Treats Psoriasis Through RHCG-Related Mechanisms.Int J Genomics. 2025 Jul 9;2025:5132158. doi: 10.1155/ijog/5132158. eCollection 2025. Int J Genomics. 2025. PMID: 40678620 Free PMC article.
-
Co-Delivery of Tacrolimus and Thymoquinone Topically by Nanostructured Lipid Carrier Gel for Enhanced Efficacy Against Psoriasis.AAPS PharmSciTech. 2025 Mar 26;26(4):90. doi: 10.1208/s12249-025-03074-y. AAPS PharmSciTech. 2025. PMID: 40133726
-
A Randomized, Double-Blind, Controlled Clinical Study on the Curative Effect of Huaier on Mild-to-Moderate Psoriasis and an Experimental Study on the Proliferation of Hacat Cells.Biomed Res Int. 2018 Aug 29;2018:2372895. doi: 10.1155/2018/2372895. eCollection 2018. Biomed Res Int. 2018. PMID: 30246016 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous